Focused On-demand Library for Procollagen galactosyltransferase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Collagen beta(1-O)galactosyltransferase 1; Glycosyltransferase 25 family member 1; Hydroxylysine galactosyltransferase 1

Alternative UPACC:

Q8NBJ5; Q8NC64


Procollagen galactosyltransferase 1, also known as Collagen beta(1-O)galactosyltransferase 1, plays a crucial role in collagen biosynthesis. It is responsible for transferring beta-galactose to hydroxylysine residues of type I collagen, facilitating the formation of the collagen triple helix. This enzyme is also involved in the biosynthesis of collagen type IV, highlighting its importance in maintaining the structural integrity of various tissues.

Therapeutic significance:

The enzyme's association with Brain small vessel disease 3, a condition characterized by cerebrovascular defects leading to developmental delays and neurological deterioration, underscores its therapeutic significance. Understanding the role of Procollagen galactosyltransferase 1 could open doors to potential therapeutic strategies for treating or managing this debilitating disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.